Mergers

Black Hawk Acquisition (BKHA) signs merger agreement with Vesicor Therapeutics

BKHA

Black Hawk Acquisition Corporation (Nasdaq: BKHA) disclosed on April 29, 2025 a business combination agreement dated April 26, 2025 with Vesicor Therapeutics, a p53 cancer drug developer.

Investor Chat

Scorecard

BKHA
Investor Impact: 9/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-08
Very highHigh evidence
Investment Attractiveness: 3.9/10, Below peersThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-08
Below peers

By the aibio.space news desk

Scientists in protective clothing working in a cleanroom
Scientists in protective clothing working in a cleanroom. Photo: usdoe, CC0, via rawpixel. The picture shows the field, not the companies named.

Black Hawk Acquisition Corporation (Nasdaq: BKHA) entered into a Business Combination Agreement dated April 26, 2025 with Vesicor Therapeutics, Inc., a California corporation, and with BH Merger Sub, Inc., a wholly owned subsidiary of the company. The company disclosed the agreement in a current report filed April 29, 2025. Under the agreement, Black Hawk would transfer out of the Cayman Islands and domesticate as a Delaware corporation, and Merger Sub would merge into Vesicor, which would survive as a wholly owned subsidiary.

Why is this important: For holders of Black Hawk's units, ordinary shares and rights, the agreement is the route to a Nasdaq-listed company that would own a development-stage cancer drug developer. Closing depends on conditions the filing describes, including a transaction financing of at least $10,000,000 that Vesicor must arrange. If the agreement is terminated, the breaching party owes a $1,000,000 break-up fee as liquidated damages.

Kent Louis Kaufman signed the April 2025 filing as chief executive officer and chairman. The 8-K does not identify the source of the $10,000,000 financing that Vesicor must arrange. In our view, the agreement asks shareholders of a blank-check company to approve a combination whose main funding is still to be raised, and the filing leaves that gap open.

What the agreement requires

The company will de-register in the Cayman Islands and continue into Delaware, a step the filing calls the domestication. On the day of closing, Merger Sub will merge with and into Vesicor, and Vesicor will survive as a wholly owned subsidiary of the public company. Vesicor, a California corporation, will reincorporate in Delaware on the business day before closing, according to the agreement.

The public company will change its name, and the company says it plans to remain listed on Nasdaq under a new ticker symbol. Each outstanding unexercised Vesicor warrant will be assumed by the public company and converted into a warrant to buy its common stock.

Closing is conditioned on Vesicor arranging a transaction financing of not less than $10,000,000. That financing may take the form of a cash equity investment, equity-linked instruments, debt instruments or other forms the agreement lists. If the agreement is terminated, the breaching party pays the other side $1,000,000 as liquidated damages.

Each Black Hawk unit consists of one ordinary share and one right. Each right entitles the holder to receive one-fifth of one ordinary share.

The business Black Hawk would own

The April 2025 filing describes Vesicor as a development-stage biopharmaceutical company focused on the development of p53-based cancer therapeutics delivered via microvesicles. That is the only product description in the April filing. The filing does not name a clinical trial or give a ClinicalTrials.gov number.

A later proxy statement, dated September 21, 2026, names the lead candidate as ecm-RV/p53. That document says the candidate is preclinical and that the company does not expect to begin preclinical and IND-enabling studies until the fourth quarter of 2026. The later document is cited here for context only.

Black Hawk's cash before the deal

The company's quarterly report for the period ended February 28, 2025 says it had cash of $101,528 and working capital of $135,561 on that date. Those figures are the latest balance-sheet numbers filed before the April 29 agreement.

The same report says the company's liquidity needs before its initial public offering were met through a payment from the sponsor. It also says funds available outside the trust account were insufficient to cover such expenses. Black Hawk holds public money in a trust account until it completes a business combination. In our view, a working capital cushion of $135,561 is thin against the cost of a merger process that still needs a $10,000,000 financing.

What comes next

Closing depends on the financing condition, the domestication and the merger steps described above.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.